An Observational Study on the Effect of Nimodipine on Cerebral Blood Flow Velocity and Oxygenation in Patients with Subarachnoid Haemorrhage

Ruby Chackupurakal¹, Marlene Gebauer¹, Fabian Dusse¹², Alexander Hartmann³, Makoto Nakamura³, Frank Wappler¹, Samir G Sakka¹⁴

¹Department of Anaesthesiology and Operative Intensive Care Medicine, Medical Center Cologne Merheim, University of Witten/Herdecke, Cologne, Germany
²Department of Anaesthesiology and Operative Intensive Care Medicine, University Hospital of Cologne, Cologne, Germany
³Department of Neurosurgery, Medical Center Cologne Merheim, University of Witten/Herdecke, Cologne, Germany
⁴Department of Intensive Care Medicine, Medical Center Mittelrhein, Koblenz, University of Mainz, Koblenz, Germany

Objective

In patients with subarachnoid haemorrhage (SAH), nimodipine is administered to prevent for cerebral vasospasm. In this prospective observational study, we examined the effect of nimodipine on cerebral blood flow velocity (BFV) (transcranial Doppler, TCD) and regional oxygen saturation (rSO₂) (near-infrared spectroscopy, NIRS) as well as its systemic haemodynamic effects.

Methods

After ethics approval, we enrolled 18 adult patients (11 females) with SAH after aneurysm rupture. After treatment of the bleeding source, patients underwent extended haemodynamic monitoring by transpulmonary thermodilution (PiCCOTM, Pulsion, Maquet Getinge Group, Feldkirchen, Germany). Measurements of systemic haemodynamics as well as cerebral oxygenation and blood flow velocity were performed 30 minutes before and after the enteral administration of nimodipine (60 mg). Data was compared by paired t-test. A p<0.05 was considered as statistically significant. Data are expressed as mean ± SD.

Results

Patients’ mean age was 59 ± 11 years. Enteral nimodipineincrease in heart rate (75 vs. 79/min, p<0.05) and cardiac index (3.27 vs. 3.58 l/min/m², p<0.05). While noe administration was associated with a decrease in mean arterial pressure (93 vs. 88 mmHg, p<0.05), an radrenaline dose and BFV did not change significantly, NIRS revealed a reduction in cerebral oxygenation, but rSO₂ values remained within a healthy range in all patients (right 71 vs. 69 %, p<0.05; left 74 vs. 72 %, p<0.05).

Conclusions

In patients with SAH, enteral nimodipine led to inconclusive changes in systemic haemodynamics. Although cerebral oxygenation as assessed by NIRS decreased after nimodipine administration, BFV remained stable.

Keywords: Cerebral blood flow velocity; Cerebral oxygenation; Nimodipine; Subarachnoid haemorrhage; Systemic haemodynamics
INTRODUCTION

Subarachnoid haemorrhage after aneurysm rupture (SAH) is associated with significant morbidity and mortality. Delayed cerebral ischemia (DCI) is a clinical syndrome of focal neurological deficits that develop in one third of patients, and is a major cause of death and disability after SAH. Although further aspects like brain injury, inflammation and microthrombosis and their influence on DCI are currently being discussed, cerebral vasospasms (CVS) remain the most serious complication of SAH, leading to DCI and infarction. CVS after SAH are described as narrowing of angiographically visible cerebral arteries and occur in 70% of patients with SAH after aneurysm rupture. Typically, CVS occur between day 3 and 4 after aneurysm rupture, their peak is between day 7 to 10 and they resolve by day 14 to 21. Nimodipine remains the only approved medication to prevent DCI. As a lipophilic antagonist of calcium channels, nimodipine acts as a cerebrovascular vasodilator. In the largest randomized multicenter double-blind placebo-controlled study, nimodipine significantly reduced cerebral infarctions and poor outcome in patients with SAH. According to the guidelines of the American Heart Association and the American Stroke Association, nimodipine should be administered orally to all patients with SAH (Class I, Level of Evidence A). Therefore, it is routinely administered (60 mg every four hours) from the time of SAH presentation through day 21.

In clinical routine, transcranial Doppler (TCD) is a widely used tool to monitor for the development of SAH-induced CVS by assessing blood flow velocity (BFV) in the intracranial arteries. Furthermore, near-infrared spectroscopy (NIRS) enables bedside brain monitoring by a non-invasive measurement of regional cerebral oxygen saturation (rSO₂) via absorption of near-infrared light of oxyhaemoglobin (Hbo), deoxyhaemoglobin (Hb), and cytochrome-oxidase. Since there is still a lack of knowledge, we studied the systemic haemodynamic effects of nimodipine (as assessed by transpulmonary thermodilution with PiCCO™ technology) as well as its impact on BFV and rSO₂ (as assessed by TCD and NIRS) in SAH patients.

METHODS

After approval from the institutional review board (Ethics Committee of the University of Witten/Herdecke, number 48/2012, chair: Prof. Dr. med. P. Gaidzik, date of approval 2 September 2013), written individual informed consent was obtained for patients who presented at our hospital with SAH. In this prospective observational study, we included 18 adult critically ill patients with SAH between August 2014 and June 2018.

RESULTS

Eighteen patients (mean age 59 ± 11 years, 11 females, 7 males) with SAH were included in this study (Table 1). Twelve aneurysms were treated with clip occlusion and five aneurysms were embolized with coils. In one case no bleeding source was found, hence no treatment was performed in this patient. After nimodipine administration a significant decrease in mean arterial pressure (MAP) (93 vs. 88 mmHg, p < 0.05) was observed together with a
concomitant increase in heart rate (75 vs. 79/min, p < 0.05). Furthermore, cardiac index (CI) increased significantly (3.27 vs. 3.58 l/min/m², p < 0.05) (Table 2). TCD showed normal and stable mean BFV in MCA and ACA before and after nimodipine administration. NIRS revealed a significant bifrontal reduction of rSO₂ (right 71 vs. 69 %, p < 0.05; left 74 vs. 72 %, p < 0.05), yet staying within a physiological range among the study population (Table 3).

Elevated BFV of both MCA and ACA was seen in one patient, with values up to 200 cm/sec (Fig. 1A and B). In this patient, nimodipine administration was associated with a further bilateral increase of BFV of MCA and ACA. While rSO₂ values remained without significant change after nimodipine administration, NIRS detected a non-significantly lower right sided cerebral oxygen saturation (69 vs. 81 %) consistent with a considerably high BFV in MCA on the same side.

DISCUSSION

In patients with SAH, we found that enteral nimodipine administration was associated with hypotension, an increase in heart rate and slightly higher noradrenaline requirements, while CI increased significantly. No significant changes in BFV in MCA and ACA were detected by TCD. Interestingly, NIRS revealed a decrease in frontal regional cerebral oxygenation, probably due to impaired cerebral autoregulation, however rSO₂ values were within a physiological range in all patients.

In healthy subjects, nimodipine has shown to be effective in increasing cerebral perfusion in spite of its hypotensive effect. Similar

Table 1. Baseline characteristics of all patients

| Patient | Age (years) | Gender | Aneurysm localization | Hunt & Hess grade | Treatment | SAPS II | SOFA |
|---------|-------------|--------|-----------------------|-----------------|-----------|---------|------|
| 1       | 76          | male   | BA                    | V               | Coiling   | 45      | 8    |
| 2       | 76          | female | PICA                  | III             | Coiling   | 38      | 9    |
| 3       | 54          | female | MCA/PICA              | III             | Clipping  | 28      | 9    |
| 4       | 62          | male   | AComA                 | I               | Clipping  | 24      | 0    |
| 5       | 44          | female | PCA                   | V               | Coiling   | 29      | 9    |
| 6       | 56          | female | AComA                 | III             | Clipping  | 25      | 8    |
| 7       | 51          | female | MCA                   | V               | Clipping  | 32      | 7    |
| 8       | 50          | female | PICA                  | V               | Coiling   | 28      | 8    |
| 9       | 50          | female | MCA                   | II              | Clipping  | 29      | 7    |
| 10      | 50          | female | PCA                   | I/II            | Clipping  | 23      | 7    |
| 11      | 62          | female | MCA                   | IV              | Clipping  | 32      | 8    |
| 12      | 80          | female | *                     | III             | -         | 46      | 7    |
| 13      | 71          | male   | ICA/PComA             | III             | Clipping  | 46      | 9    |
| 14      | 52          | male   | ICA                   | IV              | Clipping  | 35      | 6    |
| 15      | 53          | male   | PComA                 | II              | Coiling   | 39      | 12   |
| 16      | 55          | male   | BA                    | III             | Clipping  | 31      | 8    |
| 17      | 69          | female | BA                    | V               | Clipping  | 33      | 12   |
| 18      | 54          | male   | MCA                   | V               | Clipping  | 31      | 11   |

BA: Basilar artery, PICA: Posterior inferior cerebellar artery, MCA: Middle cerebral artery, AComA: Anterior communicating artery, PCA: Posterior cerebral artery, ICA: Internal carotid artery, PComA: Posterior communicating artery, SAPS: Simplified acute physiology score, SOFA: Sequential organ failure assessment.

Table 2. Systemic haemodynamics and vasopressor support before and 30 minutes after enteral administration of 60 mg of nimodipine

|                      | Before       | After       | p-value |
|----------------------|--------------|-------------|---------|
| Heart rate (1/min)   | 75 ± 19      | 79 ± 19     | <0.05   |
| MAP (mmHg)           | 93 ± 14      | 88 ± 11     | <0.05   |
| CI (l/min/m²)        | 3.27 ± 0.67  | 3.58 ± 0.84 | <0.05   |
| CPP (mmHg)           | 83 ± 17      | 78 ± 14     | <0.05   |
| Norepinephrine (µg/kg/min) | 0.25 ± 0.20 | 0.27 ± 0.22 | <0.05   |

MAP: Mean arterial pressure, CI: Cardiac index, CPP: Cerebral perfusion pressure.

Table 3. Variables of cerebral blood flow velocity and oxygenation before and 30 minutes after enteral administration of 60 mg of nimodipine

|                      | Before       | After       | p-value |
|----------------------|--------------|-------------|---------|
| BFV - MCA right (cm/sec) | 71 ± 40     | 71 ± 40     | 0.9     |
| BFV - MCA left (cm/sec)  | 67 ± 28     | 68 ± 35     | 0.87    |
| BFV - ACA right (cm/sec) | 60 ± 21     | 60 ± 33     | 0.92    |
| BFV - ACA left (cm/sec)  | 66 ± 28     | 69 ± 35     | 0.59    |
| rSO₂ right (%)         | 71 ± 9      | 69 ± 10     | <0.05   |
| rSO₂ left (%)          | 74 ± 10     | 72 ± 8      | <0.05   |

BFV: Blood flow velocity, MCA: Middle cerebral artery, ACA: Anterior cerebral artery, rSO₂: Regional cerebral oxygen saturation.

www.e-jnic.org
to our results, a decrease in arterial blood pressure with a concomitant increase in heart rate appeared without significant change of mean BFV in MCA. However, in contrast to our data, NIRS-derived regional oxygenation saturation improved after nimodipine administration\(^8\).

In patients with SAH, the effect of nimodipine is ambiguous. Nimodipine seems to be unable to alter the incidence or severity of vasospasm\(^6,12\), yet it reduces the risk of DCI and improves neurologic outcome after SAH\(^13\). If clinically significant DCI occurs, arterial hypertension is recommended to improve cerebral perfusion\(^12\). While several studies report increased cerebral blood flow (CBF) due to nimodipine, few show reduced CBF linked to decreased MAP and CPP\(^10,16\). In contrast, one retrospective study even revealed an enhanced risk of CVS with a higher need for vasoconstrictor agents associated with nimodipine administration\(^10\). Nimodipine is routinely used to prevent CVS, but its effect on patients with existing CVS might be risky. When nimodipine induces hypotension, an impaired autoregulation might lead to reduced cerebral perfusion with decreased rSO\(_2\) values in these patients. It remains unclear how many patients were indeed affected by CVS in the present study. TCD is widely used to consider CVS if mean BFV in MCA exceeds 120 cm/sec\(^16\). Overall, mean BFV in our patients remained within a physiological range. A pathologic increase of BFV only occurred in one patient in whom we found a decrease by 25 % from the baseline to be associated with DCI and neurological deficits\(^13\). This did not appear in any of our patients. Either nimodipine administration did not lead to an improvement of cerebral perfusion and oxygenation as mean BFV and rSO\(_2\) remained within the normal range anyway, or the used methods were inadequate to detect a possible improvement.

When interpreting TCD- and NIRS-derived values, one should consider that TCD mainly assesses the MCA area, while bilaterally applied oximetry sensors on the forehead mainly involve the ACA territory and only partially covers the important MCA area\(^13\). A modified application of the sensors should be considered. However, regardless of the applied location, near-infrared light only penetrates 2-2.5 cm into the head, hence NIRS only reflects the cortical region without assessing deeper regions of the brain\(^14\). In addition, NIRS measurements can be tampered by factors like fever or sweat of the skin\(^13\).

Though NIRS succeeded to detect improvement of rSO\(_2\) after intraarterial infusion of fasudil hydrochloride, a potent vasodilator, to a patient suffering from SAH-induced CVS\(^14\), its diagnostic value needs to be further investigated. Whether other methods as digital subtraction angiography or perfusion CT would be able to detect an impact of nimodipine on BFV remains uncertain, too.

Our study has several limitations. As a lipophilic vasodilator, we expected nimodipine to cause cerebrovascular dilation with elevated CBF and rSO\(_2\). Due to its low bioavailability and in accordance with previous studies\(^12,16\), it is conceivable that the gastric administration of nimodipine failed to attain therapeutic plasma concentrations needed to achieve the desired effect. However, in this clinical study, nimodipine plasma concentrations were not measured and hence a dose-effect relation cannot be analyzed. Furthermore, the sample size and the heterogeneity of the patient population are major limitations of this observational study.

**CONCLUSIONS**

In summary, enteral nimodipine is routinely used to prevent DCI, which can occur due to CVS in patients with SAH. In our study population, nimodipine showed inconclusive changes in sys-
temic haemodynamics. BFV in MCA and ACA remained stable, not supporting the idea of cerebrovascular dilation following nimodipine administration. It remains unclear why rSO$_2$ decreased bilaterally, when we assume the absence of CVS due to overall normal BFV in this study population. Further studies are required to conclude the cerebral effect of enteral nimodipine in patients with SAH.

NOTES

Conflict of interest
No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Abboud T, Andreassen H, Koeppen J, Czorlich P, Duehrsen L, Stenzig J, et al. Serum levels of nimodipine in enteral and parenteral administration in patients with aneurysmal subarachnoid hemorrhage. Acta Neurochir 2015;157:763–767.
2. Albanna W, Weiss M, Conzen C, Clusmann H, Schneider T, Reinsch M, et al. Systemic and Cerebral Concentration of Nimodipine During Established and Experimental Vasospasm Treatment. World Neurosurg 2017;102:459–465.
3. Bhatia R, Hampton T, Malde S, Kandala NB, Muammar M, Deasy N, et al. The application of near-infrared oximetry to cerebral monitoring during aneurysm embolization: a comparison with intra-procedural angiography. J Neurosurg Anesthesiol 2007;19:97–104.
4. Canova D, Roatta S, Micieli G, Bosone D. Cerebral oxygenation and haemodynamic effects induced by nimodipine in healthy subjects. Funct Neurol 2012;27:169–176.
5. Choi HA, Ko SB, Chen H, Gilmore E, Carpenter AM, Lee D, et al. Acute effects of nimodipine on cerebral vasculature and brain metabolism in high grade subarachnoid hemorrhage patients. Neurocrit Care 2012;16:363–367.
6. Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke 2012;43:1711–1737.
7. Dorsch NW, King MT. A review of cerebral vasospasm in aneurysmal subarachnoid hemorrhage Part I: Incidence and effects. J Clin Neurosci 1994;1:19–26.
8. Grasso G, Alafaci C, Macdonald RL. Management of aneurysmal subarachnoid hemorrhage: State of the art and future perspectives. Surg Neurol Int 2017;8:11.
9. Highton D, Ghosh A, Tachtsidis I, Elwell C, Smith M. Analysis of slow wave oscillations in cerebral haemodynamics and metabolism following subarachnoid haemorrhage. Adv Exp Med Biol 2014;812:195–201.
10. Jaschinski U. [Intensive care treatment after aneurysmal subarachnoid hemorrhage]. Anaesthetist 2016;65:951–970.
11. Jane JA, Adams HP, Kongable GL. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: Overall management results. J Neurosurg 1990;73:18–36.
12. Lawton MT, Yates GE. Subarachnoid Hemorrhage. N Engl J Med 2017;377:257–266.
13. Maslehaty H, Krause-Titz U, Petridis AK, Barth H, Mehdorn HM. Continuous measurement of cerebral oxygenation with near-infrared spectroscopy after spontaneous subarachnoid hemorrhage. ISRN Neurol 2012;2012:907187.
14. Mutoh T, Kobayashi S, Tamakawa N, Ishikawa T. Multichannel near-infrared spectroscopy as a tool for assisting intra-arterial fasudil therapy for diffuse vasospasm after subarachnoid hemorrhage. Surg Neurol Int 2011;2:68.
15. Mutoh T, Ishikawa T, Suzuki A, Yasui N. Continuous cardiac output and near-infrared spectroscopy monitoring to assist in management of symptomatic cerebral vasospasm after subarachnoid hemorrhage. Neurocrit Care 2010;13:331–338.
16. Stiefel MF, Heuer GG, Abrahams JM, Bloom S, Smith MJ, Maloney-Wilensky E, et al. The effect of nimodipine on cerebral oxygenation in patients with poor-grade subarachnoid hemorrhage. J Neurosurg 2004;101:594–599.
17. Yokose N, Sakatani K, Murata Y, Awano T, Igarashi T, Nakamura S, et al. Bedside assessment of cerebral vasospasms after subarachnoid hemorrhage by near infrared time-resolved spectroscopy. Adv Exp Med Biol 2010;662:505–511.
18. Zweifel C, Castellani G, Czosnyka M, Carrera E, Brady KM, Kirkpatrick PJ, et al. Continuous assessment of cerebral autoregulation with near-infrared spectroscopy in adults after subarachnoid hemorrhage. Stroke 2010;41:1963–1968.